Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $2.34 in the prior trading day, Aclaris Therapeutics Inc (NASDAQ: ACRS) closed at $2.49, up 6.41%. In other words, the price has increased by $6.41 from its previous closing price. On the day, 1.32 million shares were traded. ACRS stock price reached its highest trading level at $2.49 during the session, while it also had its lowest trading level at $2.2701.
Ratios:
Our goal is to gain a better understanding of ACRS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.88 and its Current Ratio is at 3.88. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On May 28, 2025, Wedbush started tracking the stock assigning a Outperform rating and target price of $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 19 ’24 when Mehra Anand bought 666,666 shares for $2.25 per share. The transaction valued at 1,499,998 led to the insider holds 710,030 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACRS now has a Market Capitalization of 269747232 and an Enterprise Value of 172307216. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.07 while its Price-to-Book (P/B) ratio in mrq is 2.05. Its current Enterprise Value per Revenue stands at 10.263 whereas that against EBITDA is -2.958.
Stock Price History:
The Beta on a monthly basis for ACRS is 0.45, which has changed by 0.19138753 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, ACRS has reached a high of $5.17, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 25.69%, while the 200-Day Moving Average is calculated to be 42.82%.
Shares Statistics:
The stock has traded on average 1.12M shares per day over the past 3-months and 1488930 shares per day over the last 10 days, according to various share statistics. A total of 108.33M shares are outstanding, with a floating share count of 92.30M. Insiders hold about 14.80% of the company’s shares, while institutions hold 73.48% stake in the company. Shares short for ACRS as of 1760486400 were 4689649 with a Short Ratio of 4.21, compared to 1757894400 on 5821942. Therefore, it implies a Short% of Shares Outstanding of 4689649 and a Short% of Float of 5.1599998000000005.
Earnings Estimates
A detailed examination of Aclaris Therapeutics Inc (ACRS) is currently in progress, with 5.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.12 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$0.51 and -$0.62 for the fiscal current year, implying an average EPS of -$0.54. EPS for the following year is -$0.62, with 5.0 analysts recommending between -$0.41 and -$0.87.
Revenue Estimates
7 analysts predict $1.41M in revenue for. The current quarter. It ranges from a high estimate of $2.1M to a low estimate of $700k. As of. The current estimate, Aclaris Therapeutics Inc’s year-ago sales were $4.35MFor the next quarter, 7 analysts are estimating revenue of $1.41M. There is a high estimate of $1.97M for the next quarter, whereas the lowest estimate is $700k.
A total of 8 analysts have provided revenue estimates for ACRS’s current fiscal year. The highest revenue estimate was $7.2M, while the lowest revenue estimate was $2.6M, resulting in an average revenue estimate of $5.34M. In the same quarter a year ago, actual revenue was $18.72MBased on 8 analysts’ estimates, the company’s revenue will be $4.93M in the next fiscal year. The high estimate is $10M and the low estimate is $900k.
